ArticleJACS Au2026
High-Throughput Screening Identifies Covalent Inhibitors with Unique Chemistry and Binding Modes for SARS-CoV‑2 Main Protease.
Abstract read
In one paragraph
Article in JACS Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Sandeep AtlaTexas A&M Drug Discovery Center and Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas 77843, United States.
Kai S YangTexas A&M Drug Discovery Center and Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas 77843, United States.ORCID https://orcid.org/0000-0002-1890-4169
Erol C VatanseverTexas A&M Drug Discovery Center and Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas 77843, United States.
Eun Jeong ChoTargeted Therapeutic Drug Discovery & Development Program, the University of Texas, Austin, Texas 78712, United States.
Xinyu MaTexas A&M Drug Discovery Center and Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas 77843, United States.ORCID https://orcid.org/0000-0002-4798-6095
Yugendar R AlugubelliTexas A&M Drug Discovery Center and Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas 77843, United States.
Satyanarayana NyalataTexas A&M Drug Discovery Center and Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas 77843, United States.ORCID https://orcid.org/0009-0009-6717-5941
Lauren R BlankenshipTexas A&M Drug Discovery Center and Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas 77843, United States.
Kaustav KhatuaTexas A&M Drug Discovery Center and Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas 77843, United States.ORCID https://orcid.org/0000-0002-2497-3187
Demonta ColemanTexas A&M Drug Discovery Center and Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas 77843, United States.
Xuejiao GuoTexas A&M Drug Discovery Center and Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas 77843, United States.
Rachel M SammonsTargeted Therapeutic Drug Discovery & Development Program, the University of Texas, Austin, Texas 78712, United States.ORCID https://orcid.org/0000-0003-4211-0083
Dorsa RabieTexas A&M Drug Discovery Center and Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas 77843, United States.
Banumathi SankaranMolecular Biophysics and Integrated Bioimaging, Berkeley Center for Structural Biology, Laurence Berkeley National Laboratory, Berkeley, California 94720, United States.
Tahmina PervinDepartment of Biology, College of Arts and Sciences, Texas A&M University, College Station, Texas 77843, United States.
Benjamin W NeumanDepartment of Biology, College of Arts and Sciences, Texas A&M University, College Station, Texas 77843, United States.ORCID https://orcid.org/0000-0003-1240-8954
Chia-Chuan D ChoTexas A&M Drug Discovery Center and Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas 77843, United States.
Lai Hoang Son LeTexas A&M Drug Discovery Center and Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas 77843, United States.ORCID https://orcid.org/0000-0002-2473-6309
Alan PhamTexas A&M Drug Discovery Center and Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas 77843, United States.ORCID https://orcid.org/0009-0002-4066-0110
Nagarjun R MallampudiTexas A&M Drug Discovery Center and Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas 77843, United States.
Kevin N DalbyTargeted Therapeutic Drug Discovery & Development Program, the University of Texas, Austin, Texas 78712, United States.ORCID https://orcid.org/0000-0001-9272-5129
Shiqing XuTexas A&M Drug Discovery Center and Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas 77843, United States.ORCID https://orcid.org/0000-0001-6260-9290
Wenshe Ray LiuTexas A&M Drug Discovery Center and Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, Texas 77843, United States.ORCID https://orcid.org/0000-0002-7078-6534
Funding
User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Gregory L Hura · 2017 to 2026
$28.6MUse of the Noncanonical Amino Acid Mutagenesis Technique in Combination with Other Approaches to Study Functions of Posttranslational Lysine Modifications in ProteinsR35GM145351 · NIGMS · TEXAS A&M UNIVERSITY · PI Wenshe Ray Liu · 2022 to 2026
$2.6MDevelopment of fluorogenic and chemiluminogenic main protease substrates for cellular and in vivo imaging of SARS-CoV-2R21EB032983 · NIBIB · TEXAS A&M UNIVERSITY · PI LIU, WENSHE RAY · 2022 to 2023
$411kThe Development of Reversible Covalent PROTAC Technology as a New Anti-COVID-19 StrategyR21AI164088 · NIAID · TEXAS A&M UNIVERSITY · PI XU, SHIQING · 2021 to 2022
$406kNIAID NIH HHS R21 AI164088NIBIB NIH HHS R21 EB032983NIGMS NIH HHS P30 GM124169NIGMS NIH HHS R35 GM145351
Abstract
Using an easily scalable SARS-CoV-2 main protease (M
Indexed as
Covalent InhibitorMain ProteaseNucleophilic Acyl SubstitutionNucleophilic Aromatic SubstitutionSARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.